Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies.

Introduction

The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed. Ceftolozane/tazobactam is a treatment option that targets multidrug-resistant pathogens and may offer improved patient outcomes compared to traditional antibiotics that are now often ineffective.

Objectives

Our objective was to collate findings from comparative efficacy studies to assess the efficacy of ceftolozane/tazobactam for the indications of complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Methods

Two systematic literature reviews were conducted, including randomized controlled trials comparing ceftolozane/tazobactam with other interventions for complex intra-abdominal infection, complex urinary tract infection, ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia indications. The outcomes of interest were mortality, clinical cure and microbiological eradication.

Results

Ceftolozane/tazobactam was determined to be non-inferior to comparators for all outcomes of interest. All-cause mortality for ceftolozane/tazobactam displayed non-inferiority to meropenem, with the largest numerical differences in all-cause mortality displayed in susceptible patients, such as those with severe renal impairment. Similarly, the clinical cure and microbiological eradication for ceftolozane/tazobactam demonstrated non-inferiority compared to meropenem or levofloxacin.

Conclusions

These reviews support the role of ceftolozane/tazobactam as an alternative option, particularly when MDR pathogens are suspected or documented. Their findings may contribute to the standardization of treatment guidelines, ultimately helping to reduce the clinical and economic burdens associated with these infections.